Substituted quinoxalines as inhibitors of fatty acid binding protein

US8889683B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Clifford C. Cheng · Cambridge, US
• Gerald W. Shipps, Jr. · Stoneham, US
• Xiaohua Huang · Qingdao, CN
• Ying Huang · Berkeley Heights, US
• Ning Shao · Clark, US
• Ashwin U. Rao · Avenel, US
• Anandan Palani · Bound Brook, US
• Peter Orth · New York, US
• Johannes H. Voigt · Cranford, US
• Robert Jason Herr · Voorheesville, US
• Lana Michele Rossiter · Clifton Park, US
• Qi Zeng · Santa Clara, US
• Xianfeng Sun · Guilderland, US

Key dates

• Filing date: Sep 23, 2011
• Grant date: Nov 18, 2014
• Expiry date: Dec 2, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to novel quinoxaline compounds of Formula I:as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.